ALPN News and Press, Alpine Immune Sciences Inc. From 04/10/24

-- Povetacicept administered subcutaneously once every four weeks continues to be well tolerated in IgA nephropathy, with UPCR reductions of greater than 60% observed at 36 weeks, associated with remission, resolution of hematuria, and stable renal function (eGFR) -- -- Company reports ...

- Alpine is a clinical stage biotechnology company focused on discovering and developing innovative, protein-based immunotherapies - - Alpine’s lead product, povetacicept, demonstrated best-in-class potential in patients with IgA nephropathy (IgAN); Phase 3 to initiate in H2 2024...

2024-04-10 12:41:07 ET More on Alpine Immune Sciences Alpine Immune Sciences, Inc. (ALPN) Q4 2023 Earnings Call Transcript Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug Alpine Immune Sciences Q4 2023 Earnings Preview Wolfe starts A...

-- The Company will present updated data in a late-breaking poster session for povetacicept in IgA nephropathy patients -- -- The Company will host an investor event the same day concurrently with the poster presentation on April 15 th -- Alpine Immune Sciences, Inc. (...

-- Povetacicept demonstrates greater reductions in disease activity in a mouse model of lupus compared to WT TACI-Ig or B cell depletion -- -- Povetacicept exhibits greater distribution to disease-related end organs compared with WT TACI-Ig -- -- A phase 2 study in SLE (DENALI) ...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in the H.C. Wainwright 2 nd Annual Autoimmune & Inflammator...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN) is the focus of IBN's latest stock spotlight. The company's shares have moved 15.08% on the day to $40.82. Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunothera...

A look at the top 10 most actives in the United States Ontrak Inc. (OTRK) rose 214.5% to $0.5975 on volume of 79,666,583 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 5.0% to $3.7703 on volume of 36,416,698 shares Enveric Biosciences Inc. (ENVB) rose 35.5% to $1.49 on vol...

2024-03-18 19:24:06 ET Alpine Immune Sciences, Inc. (ALPN) Q4 2023 Results Conference Call March 18, 2024 04:30 PM ET Company Participants Temre Johnson - Senior Director, Investor Relations and Corporate Communications Mitchell Gold - Executive Chairman and Chief Ex...

2024-03-18 16:38:49 ET Gainers: National CineMedia ( NCMI ) +8% . Inventiva ( IVA ) +6% . Alpine Immune Sciences ( ALPN ) +5% . Leslie's ( LESL ) +5% . Maxeon Solar Technologies ( MAXN ) +5% . Losers: DLocal  ( DLO...